Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.38 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417962 | 0.79 | DAO (0.37) | ERCC1DNASE1FEN1ERCC4ALDH1A1 | |
| SCHEMBL27701056 | 0.72 | BRD4 (0.33) | — | |
| SCHEMBL2181559 | 0.72 | — | — | |
| SCHEMBL30750905 | 0.72 | CYP1A2 (0.41) | CYP1A2ERCC1DNASE1FEN1ERCC4 | |
| SCHEMBL8978393 | 0.71 | RAB9A (0.36) | CYP1A2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL5796882 | 0.70 | KDM4E (0.41) | ERCC1DNASE1FEN1ERCC4ALDH1A1 | |
| SCHEMBL7965650 | 0.70 | ADRA2B (0.40) | CYP1A2ALDH1A1ALOX12MAPTHPGD | |
| SCHEMBL9277794 | 0.69 | — | — | |
| SCHEMBL6448705 | 0.69 | CYP1A2 (0.42) | CYP1A2ALDH1A1ALOX12MAPTHPGD | |
| SCHEMBL3323716 | 0.67 | ALDH1A1 (0.39) | CYP1A2ALDH1A1ALOX12MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910454-B2 | TRIETHANOLAMINE PERCHLORATO (TRIFLATO) METAL INNER COMPLEX COORDINATION POLYMERS AS ADDITIVES FOR SYNTHETIC POLYMERS | CATENA ADDITIVES GMBH & CO KG (DE) | 2016-11-30 | — | — | EP | disclosed |
| EP-1910454-B1 | TRIETHANOLAMINE PERCHLORATO (TRIFLATO) METAL INNER COMPLEX COORDINATION POLYMERS AS ADDITIVES FOR SYNTHETIC POLYMERS | CATENA ADDITIVES GMBH & CO KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1910454-A1 | TRIETHANOLAMINE PERCHLORATO (TRIFLATO) METAL INNER COMPLEX COORDINATION POLYMERS AS ADDITIVES FOR SYNTHETIC POLYMERS | CATENA Additives GmbH & Co. KG (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136191-A1 | TRIETHANOLAMINE PERCHLORATO (TRIFLATO) METAL INNER COMPLEX COORDINATION POLYMERS AS ADDITIVES FOR SYNTHETIC POLYMERS | CATENA ADDITIVES GMBH & CO. KG (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060122201-A1 | Uracil-thioether | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | US | disclosed |
| US-20060100224-A1 | Piperidine ouracil used as a medicament for treating bacterial infections | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1499612-A1 | PIPERIDINE OURACIL USED AS A MEDICAMENT FOR TREATING BACTERIAL INFECTIONS | Bayer HealthCare AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| EP-1480958-A1 | URACIL-THIOETHER | Bayer HealthCare AG (DE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072574-A1 | PIPERIDINE OURACIL USED AS A MEDICAMENT FOR TREATING BACTERIAL INFECTIONS | BAYER HEALTHCARE AG (DE) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072551-A1 | URACIL-THIOETHER | BAYER HEALTHCARE AG (DE) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003053959-A1 | HETEROCYCLYLAMINO CARBONYLURACILS | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003000664-A1 | URACIL DERIVATIVES AND THE USE THEREOF FOR TREATING BACTERIAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000665-A1 | ANTIBACTERIAL URACIL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122201-A1 | Uracil-thioether | TPMT, HPRT1, UNG | CYP1A2 834/4885ERCC1 234/4885DNASE1 673/4885 |
| US-20060100224-A1 | Piperidine ouracil used as a medicament for treating bacterial infections | BPGM, AMPD2, AMPD1 | CYP1A2 3137/4885ERCC1 3696/4885DNASE1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.